COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs

被引：123

作者：

Warner, Timothy D. ^{[1
]}

Mitchell, Jane A. ^{[2
]}

机构：

[1] Barts & London, Queen Marys Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England

[2] Imperial Coll Sch Med, Royal Brompton Hosp, Unit Crit Care Med, London, England

来源：

LANCET | 2008年 / 371卷 / 9608期

基金：

英国惠康基金;

关键词：

D O I：

10.1016/S0140-6736(08)60137-3

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：270 / 273

页数：4

共 22 条

[1]

Use of nonsteroidal Antiinflammatory drugs an update for clinicians - A scientific statement from the American Heart Association [J].

Antman, Elliott M. ;

Bennett, Joel S. ;

Daugherty, Alan ;

Furberg, Curt ;

Roberts, Harold ;

Taubert, Kathryn A. .

CIRCULATION, 2007, 115 (12) :1634-1642

[2]

CRONBERG S, 1984, SCAND J HAEMATOL, V33, P155

[3]

Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib [J].

Farkouh, M. E. ;

Greenberg, J. D. ;

Jeger, R. V. ;

Ramanathan, K. ;

Verheugt, F. W. A. ;

Chesebro, J. H. ;

Kirshner, H. ;

Hochman, J. S. ;

Lay, C. L. ;

Ruland, S. ;

Mellein, B. ;

Matchaba, P. T. ;

Fuster, V. ;

Abramson, S. B. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (06) :764-770

[4]

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial [J].

Farkouh, ME ;

Kirshner, H ;

Harrington, RA ;

Ruland, S ;

Verheugt, FW ;

Schnitzer, T ;

Burmester, GR ;

Mysler, E ;

Hochberg, MC ;

Doherty, M ;

Ehrsam, E ;

Gitton, X ;

Krammer, G ;

Mellein, B ;

Gimona, A ;

Matchaba, P ;

Hawkey, CJ ;

Chesebro, JH .

LANCET, 2004, 364 (9435) :675-684

[5]

Balancing prostanoid activity in the human vascular system [J].

Flavahan, Nicholas A. .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (03) :106-110

[6]

Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study [J].

Graham, DJ ;

Campen, D ;

Hui, R ;

Spence, M ;

Cheetham, C ;

Levy, G ;

Shoor, S ;

Graham, D .

LANCET, 2005, 365 (9458) :475-481

[7]

Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities [J].

Grosser, T ;

Fries, S ;

FitzGerald, GA .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) :4-15

[8]

The pharmacology of selective inhibition of COX-2 [J].

Grosser, Tilo .

THROMBOSIS AND HAEMOSTASIS, 2006, 96 (04) :393-400

[9]

NSAIDs, coxibs, and the intestine [J].

Hawkey, C. J. .

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2006, 47 :S72-S75

[10]

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: Results of a collaborative meta-analysis [J].

Henry, D ;

Lim, LLY ;

Rodriguez, LAG ;

Gutthann, SP ;

Carson, JL ;

Griffin, M ;

Savage, R ;

Logan, R ;

Moride, Y ;

Hawkey, C ;

Hill, S ;

Fries, JT .

BRITISH MEDICAL JOURNAL, 1996, 312 (7046) :1563-1566

← 1 2 3 →